Loading
A phase 3 trial testing Lerotinib in oesophageal cancer, now recruiting.
Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer is a phase 3 interventional study registered as NCT04415853, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Oesophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study. Planned enrolment is 416 participants (estimated). The study started in 2021-01-21 and primary completion is expected in 2026-08. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/